research articles ↓
October 21st, 2009, by David Pascoe | research
Always wanted to have a blog or little corner of the internet you could call your own ? Well now you can. Every registered member of the Rosacea Support Community can have their very own blog area.
So please feel free to start your own Rosacea Community Blog.
Why would I want one of those ?
Your own blog will allow you post your thoughts, ideas, …
July 28th, 2009, by David Pascoe | ocular rosacea, research
The following abstracts don’t deserve a Rosacea News item on their own, but are interesting enough to give a mention here in this Abstract Roundup. Elidel no better than Metrogel for lumps and bumps of rosacea. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol. 2009 …
July 2nd, 2009, by David Pascoe | ocular rosacea, research
It is good to see more published research backing topical cyclosporine (Restasis, Allergan) as a treatment for ocular rosacea. Restasis (cyclosporine ophthalmic emulsion 0.05%) has been shown to increase tear production and improve the quality of naturally produced tears and is the first approved therapeutic agent for the …
June 19th, 2009, by David Pascoe | research
Here is an announcement from RosaceaCare: “Earlier this year, we announced that four important and popular rosacea products that had been unavailable for many months would thereafter, by special arrangement with the originator, be manufactured and distributed by the Rosacea Care Company. We are pleased to tell you that the first of these, the much-loved Vita-Oil, will be released and ready to ship this …
June 3rd, 2009, by David Pascoe | clinical trials, doxium, research
Thanks to a comment from Sophie on the post rosacea and doxium (calcium dobesilate) we know that Dr. Cuevas who is responsible for several papers on Dobesilate, is accepting people to try it as a treatment for rosacea. Thanks for the info Sophie. Calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a vasoactive drug with presumed effects on endothelial integrity, capillary permeability and blood viscosity. It …